“GLP-1 weight-loss drugs have no major downsides.”
GLP-1 drugs do have real downsides: stomach side effects are common, some people stop because of them, and most of the lost weight often returns after stopping.
GLP-1 drugs can bring large benefits, but they come with common side effects, ongoing treatment and follow-up, and a good chance of weight regain if you stop. The balance differs by person and product.
Ask your prescriber about your expected absolute benefit, common and serious risks, how side effects would be managed, and the plan if treatment becomes unavailable or you want to stop.
Safety note: These are prescription medicines with product-specific contraindications and warnings, including pancreatitis, gallbladder disease, dehydration-related kidney injury and severe gastrointestinal reactions. Compounded products require separate quality and dosing review.
Talk to a healthcare professional if: you are starting, stopping or changing a GLP-1 drug, or you have severe or lasting stomach pain, vomiting or signs of dehydration while taking one.
Large randomized trials show substantial weight and cardiovascular benefits for selected patients, along with frequent gastrointestinal effects and more treatment discontinuation than placebo. A follow-up study found substantial weight regain after semaglutide stopped. Current prescribing information also lists uncommon but serious risks.
GLP-1 drugs do have real downsides: stomach side effects are common, some people stop because of them, and most of the lost weight often returns after stopping. In a 68-week trial, 4.5 percent of people on semaglutide stopped because of stomach side effects versus 0.8 percent on placebo, and a year after stopping, people had regained about two-thirds of the weight they lost. The same medicines also produced large weight loss and, in people with heart disease, fewer heart attacks, strokes and heart deaths.
- Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725
- Novo Nordisk. WEGOVY (semaglutide) prescribing information. US Food and Drug Administration, 2026